Answers are grounded in this paper and cite their sources.
PURPOSE: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC). The individual response to 177-lutetium prostate specific membrane antigen radioligand therapy (Lu-PSMA) is under current investigation regarding the genomic profile of patients with mCRPC. MATERIALS AND METHODS: ). Specifically, subgroup analyses were performed for patients with Lu-PSMA-treated mCRPC. RESULTS: patients had similar outcomes as no mutated patients. CONCLUSION: patients.
No takes yet. Share an insight, caveat, or question.
Wenzel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: